ESCC cells and PDX models with cyclin dependent kinase inhibitor 2A (CDKN2A) or CDKN2B loss were more sensitive to palbociclib and ribociclib treatment than cells with wild-type genes [37]. This evidence concerns the gene CDKN2A and esophageal squamous cell carcinoma.